Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 8Completed 5Terminated 3Withdrawn 2Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1NET 1Endocrine 1

Conditions

Sarcoma 1Recurrence 1Neuroendocrine Tumors 1Neoplasm Metastasis 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Yttrium-90 × Clear all
NCT04790708 2021-03-10

FENET-2016

University Hospital of Ferrara

Phase NA Unknown
250 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01898962 2013-07-15

Definitive Therapy for Oligometastatic Solid Malignancies

Rocky Mountain Cancer Centers

Phase 2 Unknown
110 enrolled
Sarcoma

Neoplasm Metastasis, Recurrence, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡